Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality ...

Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course ...

Projected by some analysts as a future blockbuster, Isembyld is the first “muscle-targeted” treatment for the disease and, in ...

Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to ...

AI is evolving from interactive chats to automated workloads driven by agentic tools, compressing timelines and enabling faster outcomes. A new reference architecture running on the Dell Pro Max with ...

Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success ...

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall Street analysts and a closer look at an industry-leading partnership streak.

Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three ...

As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings ...

The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company." ...

First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers ...

The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.